1. Metabolic mediators determine the association of antinuclear antibody subtypes with specific clinical symptoms in systemic sclerosis
    Anna Stochmal et al, 2021, Advances in Medical Sciences CrossRef

  2. Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases


    Yoshiya Tanaka et al, 2020, ImmunoTargets and Therapy CrossRef
  3. The effect of CX3CL1/ CX3CR1 signal axis on microglia in central nervous system diseases
    Jianhua Zhao et al, 2023, Journal of Neurorestoratology CrossRef
  4. Upregulation of CX3CR1 expression in circulating T cells of systemic lupus erythematosus patients as a reflection of autoimmune status through characterization of cytotoxic capacity
    Qi Li et al, 2024, International Immunopharmacology CrossRef
  5. Role of soluble fractalkine, GFAP and CD163 in cognitive functions after open heart surgery in diabetic and non-diabetic patients
    Arif OZBAY et al, 2022, Acibadem Universitesi Saglik Bilimleri Dergisi CrossRef
  6. FKN Facilitates HK-2 Cell EMT and Tubulointerstitial Lesions via the Wnt/β-Catenin Pathway in a Murine Model of Lupus Nephritis
    Dongdong Fu et al, 2019, Frontiers in Immunology CrossRef
  7. Elevated levels of inflammatory plasma biomarkers are associated with risk of HIV infection
    Samantha McInally et al, 2021, Retrovirology CrossRef
  8. Decreased CX3CL1 Levels in the Cerebrospinal Fluid of Patients With Alzheimer’s Disease
    Juan R. Perea et al, 2018, Frontiers in Neuroscience CrossRef
  9. Rationale for and clinical development of anti-fractalkine antibody in rheumatic diseases
    Sei Muraoka et al, 2020, Expert Opinion on Biological Therapy CrossRef
  10. Neuropsychiatric lupus erythematosus: Focusing on autoantibodies
    Jianing Wang et al, 2022, Journal of Autoimmunity CrossRef